AbbVie EBITDA 2010-2024 | ABBV

AbbVie EBITDA for the quarter ending December 31, 2024 was $0.612B, a 88.39% decline year-over-year.

  • AbbVie 2024 EBITDA was 17.523B, a 18.33% decline from 2023.
  • AbbVie 2023 EBITDA was 21.455B, a 19.29% decline from 2022.
  • AbbVie 2022 EBITDA was 26.584B, a 0.53% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

AbbVie EBITDA 2010-2024 | ABBV

  • AbbVie 2024 EBITDA was 17.523B, a 18.33% decline from 2023.
  • AbbVie 2023 EBITDA was 21.455B, a 19.29% decline from 2022.
  • AbbVie 2022 EBITDA was 26.584B, a 0.53% increase from 2021.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$823.1B
Johnson & Johnson (JNJ)$380.1B
Novo Nordisk (NVO)$374.3B
Roche Holding AG (RHHBY)$259.5B
Novartis AG (NVS)$218.5B
Merck (MRK)$216.5B
Pfizer (PFE)$146.7B
Sanofi (SNY)$136B
Bayer (BAYRY)$22B
Innoviva (INVA)$1.1B